Identification of differentially expressed genes following treatment of monkey kidney cells with the mycotoxin fumonisin B(1).
Fumonisin B(1) (FB(1)) is a mycotoxin produced by the phytopathogenic fungus Fusarium moniliforme, which structurally resembles sphingoid bases. FB(1) perturbs sphingolipid synthesis by inhibiting the activity of ceramide synthase. Depending on the host, ingestion of FB(1) causes equine leukoencephalomalacia or porcine pulmonary edema. It is also carcinogenic to rats and may play a role in certain human cancers. Previous studies showed that FB(1) repressed specific isoforms of protein kinase C and cyclin-dependent kinase 2 (CDK2) activity. Conversely, FB(1) induced expression of CDK inhibitors, p21(Waf1/Cip1), p27(Kip1), and p57(Kip2) in monkey kidney cells (CV-1). Consequently, FB(1) treatment of CV-1 cells leads to cell-cycle arrest and apoptosis. The baculovirus IAP gene (inhibitor of apoptosis), which blocks tumor necrosis factor (TNF)-induced apoptosis, protects several fibroblast cell types from apoptosis, suggesting the TNF pathway is important for FB(1)-induced apoptosis. To identify genes that are induced by FB(1), we used a PCR-based subtraction approach. Eight genes that showed high similarity (> 90%) to known mammalian genes were identified. These genes included: tumor necrosis factor type 1 receptor associated protein 2 (TRAP2), human leukemia virus receptor (GLVR1), human Scaffold attachment factor A (SAF-A) also called heterogeneous nuclear ribonucleoprotein U (hnRNP-U), human protein kinase C-binding protein (RACK7), human oligosaccharyl transferase STT3 subunit, mouse WW-domain binding protein 2 (WBP2), human fibronectin, and an unknown human clone. The ability of FB(1) to alter gene expression and signal transduction pathways may be necessary for its carcinogenic and toxic effects.
Zhang
Y
Y
Dept. of Plant Pathology, University of Nebraska, 68503, Lincoln, NE, USA.
Jones
C
C
Dickman
M B
MB
D000818:Animals; D015703:Antigens, CD / Q000235:genetics; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D001483:Base Sequence; D015152:Blotting, Northern; D002264:Carboxylic Acids / Q000633:toxicity*; D002274:Carcinogens, Environmental / Q000633:toxicity*; D002522:Chlorocebus aethiops; D015853:Cysteine Proteinase Inhibitors; D037341:Fumonisins; D005786:Gene Expression Regulation / Q000187:drug effects* / Q000235:genetics; D015151:Immunoblotting; D051034:Inhibitor of Apoptosis Proteins; D007668:Kidney / Q000166:cytology / Q000187:drug effects; D009183:Mycotoxins / Q000633:toxicity*; D016133:Polymerase Chain Reaction; D015398:Signal Transduction / Q000235:genetics; D013107:Sphingolipids / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics / Q000378:metabolism; D014764:Viral Proteins / Q000187:drug effects / Q000235:genetics
D015703:Antigens, CD; D002264:Carboxylic Acids; D002274:Carcinogens, Environmental; D015853:Cysteine Proteinase Inhibitors; D037341:Fumonisins; D051034:Inhibitor of Apoptosis Proteins; D009183:Mycotoxins; D013107:Sphingolipids; D014409:Tumor Necrosis Factor-alpha; D014764:Viral Proteins; C086430:inhibitor of apoptosis, Nucleopolyhedrovirus; C056933:fumonisin B1